KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreWith 17 nationalities from both hemispheres represented among our employees, there is a good chance we speak the same language as you. From our multicultural employees, we draw our innovation strength in diversifying our approaches to solve our clients' issues and enrich ourselves in the process.
While we strive to offer the best technologies and solutions to our clients, we believe the key of our success and sustained growth lays in our employees well-being. We offer competitive work-life balance packages and are open-minded to our employees feedback. The open door culture we practice daily and the great esteem we have of our team reflects highly in our growth, even in challenging years: despite the covid-19 pandemic, our staff increased by more than 50% since 2019.
Since we are the global cell-line development leader, we are always looking for better ways of doing our business. We believe that innovation, whether disruptive or incremental, requires bright and open minds. This is why almost 30% of our employees hold a PhD, and about a quarter have a master degree.
We also believe science is about identifying bias and learning to get away from them to think better. We apply this principle as hollisticaly as possible and belive this a key factor in how close our leadership gender representation is to the overall gender repartition in our employees.
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.